FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



Date: 04th February, 2025

To,

BSE Limited

Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730

<u>Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Dear Sir / Madam,

We wish to inform you that the Board of Directors of the Company at their meeting held today have took note of the resolution passed by the Management Committee to Incorporate a Wholly Owned Subsidiary named Fredun Retail Private Limited.

The Board Meeting commenced at 03:30 p.m. and concluded at 07:45 p.m.

Kindly oblige and take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited

Jinkal Shah Company Secretary and Compliance Officer Membership No.: A40722



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



ANNEXURE-I

Details required under SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

SR.NO.	PARTICULARS	DETAILS
a.	Name of the target entity, details in brief such as	Name: Fredun Retail Private
	size, turnover etc.	Limited
		Cina /Tanana arana Nata Aranali aslala
b.	Whether the acquisition would fall within related	Size/Turnover: Not Applicable Upon allotment of shares, the
D.	party transaction(s) and whether the promoter/	new Wholly Owned Subsidiary
	promoter group/ group companies have any	would be a related party to the
	interest in the entity being acquired? If yes,	Company.
	nature	Company.
	of interest and details thereof and whether the	
	same is done at "arm's length."	
C.	Industry to which the entity being acquired	Retail Industry
,	belongs;	
d.	Objects and impact of acquisition (including but	Expand Retail Chain of the
	not limited to, disclosure of reasons for	Company.
	acquisition of target entity, if its business is outside the main line of business of the listed	
	entity);	
e.	Brief details of any governmental or regulatory	Not Applicable
	approvals required for the acquisition;	
f.	Indicative time period for completion of the	Not applicable
	acquisition;	
g.	Consideration - whether cash	100% subscription to the share
	consideration or share swap or any other form	capital in cash.
h.	and details of the same;	at face value non chare
11.	Cost of acquisition and/or the price at which the shares are acquired;	at face value per share.
i.	Percentage of shareholding / control acquired	100%
	and / or number of shares acquired;	
j.	Brief background about the entity acquired in	Not Applicable
	terms of products/line of business acquired, date	
	of incorporation, history of last 3 years turnover,	
	country in which the acquired entity has	
	presence and any other significant information	
	(in brief);	

